ArticleJournal of multidisciplinary healthcare2025
Interplatform Agreement Between Liver Steatosis Analysis and Ultrasound-Guided Attenuation Parameter in the Evaluation of Hepatic Steatosis.
Article in Journal of multidisciplinary healthcare, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Liver steatosis analysis (LiSA) and the ultrasound-guided attenuation parameter (UGAP) are recently introduced commercially available techniques for the non-invasive evaluation of hepatic steatosis. This study aimed to assess the interplatform agreement between LiSA and UGAP in quantifying hepatic fat content. Methods: Individuals diagnosed with or suspected of having fatty liver disease were included in the study. The overall interplatform agreement between LiSA and UGAP was assessed. The cohort was classified into 8 groups: 4 groups based on steatosis severity (S0-S3) and 4 groups based on predominant etiologies including non-alcoholic fatty liver disease, alcoholic liver disease, drug-induced fatty liver disease, and other causes. Paired-sample Results: A cohort of 357 patients with available LiSA, UGAP, and controlled attenuation parameter measurements were included in the study. No significant differences were observed between LiSA and UGAP values ( Conclusion: LiSA and UGAP exhibited excellent interplatform agreement and can be used interchangeably for longitudinal monitoring of patients with hepatic steatosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.